Literature DB >> 20303805

Review of direct anatomical open surgical management of atherosclerotic aorto-iliac occlusive disease.

K W H Chiu1, R S M Davies, P G Nightingale, A W Bradbury, D J Adam.   

Abstract

BACKGROUND: Aortofemoral bypass(AFB), iliofemoral bypass(IFB), and aortoiliac endarterectomy(AIE) are the three most common techniques for anatomical open surgical revascularisation for patients with aorto-iliac occlusive disease(AIOD), but the optimal method of reconstruction is unknown. AIMS: To review and compare mortality, morbidity and short- and long-term patency rates for AFB, IFB and AIE in patients with AIOD reported in the English language literature
METHODS: A MEDLINE(1970-2007) and Cochrane Library search for articles relating to AFB, IFB, AIE and AIOD was undertaken. Studies were included if: a) patency rates based on life-tables were available, and b) patient/study characteristics were reported.
RESULTS: 29 studies(5738 patients) for AFB, 11 studies(778 patients) for IFB and 11 studies(1490 patients) for AIE were included. Operative mortality was 4.1% for AFB, 2.7% for IFB and 2.7% for AIE (p<0.0001). Systemic morbidity was 16.0% for AFB, 18.9% for IFB and 12.5% for AIE (p<0.05). Overall 5-year primary patency rates were 86.3%, 85.3% and 88.3% for AFB, IFB and AIE, respectively (p=NS).
CONCLUSION: Aorto-iliac endarterectomy was associated with significantly lower peri-operative morbidity and mortality rates compared with bypass grafting. All three techniques were equally effective in terms of long-term patency.

Entities:  

Mesh:

Year:  2010        PMID: 20303805     DOI: 10.1016/j.ejvs.2009.12.014

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  20 in total

Review 1.  Current state of diagnosis and management of critical limb ischemia.

Authors:  Dan Clair; Samir Shah; John Weber
Journal:  Curr Cardiol Rep       Date:  2012-04       Impact factor: 2.931

Review 2.  Strategies for managing aortoiliac occlusions: access, treatment and outcomes.

Authors:  Daniel G Clair; Jocelyn M Beach
Journal:  Expert Rev Cardiovasc Ther       Date:  2015-05

3.  Outcomes after redo aortobifemoral bypass for aortoiliac occlusive disease.

Authors:  Salvatore T Scali; Bradley M Schmit; Robert J Feezor; Adam W Beck; Catherine K Chang; Alyson L Waterman; Scott A Berceli; Thomas S Huber
Journal:  J Vasc Surg       Date:  2014-03-21       Impact factor: 4.268

4.  Comparison of Direct and Less Invasive Techniques for the Treatment of Severe Aorto-Iliac Occlusive Disease.

Authors:  Kimberly C Zamor; Andrew W Hoel; Irene B Helenowski; Adam W Beck; Joseph R Schneider; Karen J Ho
Journal:  Ann Vasc Surg       Date:  2017-07-21       Impact factor: 1.466

Review 5.  Iliac arteries: how registries can help improve outcomes.

Authors:  Charles Ross Tapping; Raman Uberoi
Journal:  Semin Intervent Radiol       Date:  2014-12       Impact factor: 1.513

Review 6.  Bypass surgery in limb salvage: inflow procedures.

Authors:  Jean Bismuth; Cassidy Duran
Journal:  Methodist Debakey Cardiovasc J       Date:  2013-04

Review 7.  [Occlusion of the aorta and iliac arteries].

Authors:  J Kosan; H Riess; G Atlihan; H Diener; T Kölbel; E S Debus
Journal:  Chirurg       Date:  2014-09       Impact factor: 0.955

8.  Abdominal aortic occlusion of young adults.

Authors:  Federico Bucci; Leslie Fiengo; Samer Hamati; Philippe Plagnol
Journal:  Interact Cardiovasc Thorac Surg       Date:  2011-11-18

9.  Treatment of Aortoiliac Occlusive Disease: Medical versus Endovascular versus Surgical Therapy.

Authors:  Mireille Astrid Moise; Vikram S Kashyap
Journal:  Curr Treat Options Cardiovasc Med       Date:  2011-04

10.  Management of Extensive Aorto-Iliac Disease: A Systematic Review and Meta-Analysis of 9319 Patients.

Authors:  Murtaza Salem; Mohammed Sayed Hosny; Federica Francia; Morad Sallam; Athanasios Saratzis; Prakash Saha; Sanjay Patel; Said Abisi; Hany Zayed
Journal:  Cardiovasc Intervent Radiol       Date:  2021-03-03       Impact factor: 2.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.